Mitsubishi Kasei Corporation

Mitsubishi Tanabe Pharma Corporation

Subaru Corporation

Toyota Jidosha Kabushiki Kaisha

Fuji Jukogyo Kabushiki Kaisha

Mitsubishi Pharma Corporation

Shinya Inoue

Hiroyuki Satoh

Masakazu Fujio

Kazuo Suzuki

Kohei Umezu

Toshifumi Matsumoto

Yasuhiro Egi

Tetsuo Sekiya

Masao Taniguchi

Tadashi Shirasaka

Hiromi Okushima

Chiaki Hyodo

Isamu Nagasawa

Tetsuo Jikihara

Taichi Takahashi

Takehisa Tsukada

Takatomo Watamori

Mayumi Hirata

Kouichi Imamura

Masayuki Mitsuka

Tetsuro Shinpuku

Hiroko Suzuki

Jyunya Okamura

A contact state determination apparatus to be applied to a vehicle includes right and left frame lateral acceleration sensors, a vehicle compartment acceleration sensor, and a contact state determination processor. The contact state determination processor is configured to determine a contact state of the vehicle, based on outputs of the right and left frame lateral acceleration sensors and the vehicle compartment acceleration sensor. The contact state determination processor is configured to determine that the contact state is an oblique contact when: the right and left frame lateral acceleration sensors detect the lateral acceleration rates that are in a same direction and are greater than or equal to a predetermined value; and the longitudinal acceleration rate detected by the vehicle compartment acceleration sensor or an integrated value of the longitudinal acceleration rate is greater than or equal to a predetermined oblique contact determination value.

Contact state determination apparatus

An airbag device includes an airbag body that inflates and deploys between a foot of a seated person and a floor panel of a vehicle. The airbag body includes: a rear inflating portion inflatable rearwardly from a heel of the seated person and upwardly higher than a bottom face of the foot in the inflation and deployment form of the airbag body, and a front inflating portion inflatable forwardly from a toe of the seated person and upwardly higher than a bottom face of the foot in the inflation and deployment form of the airbag body.

Airbag device

There is provided a front vehicle body structure. A radiator panel lower is mounted between front ends of side frames, crash boxes at the front ends of the side frames, and a bumper beam between front ends of the crash boxes. The radiator panel lower includes a bracket offset toward the inside in the vehicle width direction from the side frame. Upon an offset front collision, a shock load is absorbed by an axial compression deformation of one of the crash boxes and a drag of the side frames. Upon a full-overlap front collision, the right and left crash boxes are subjected to the axial compression deformation, and the shock load is input to the bracket, thereby bending the side frames. Accordingly, and a sufficient axial compression deformation of the crash boxes is secured, and the shock load is absorbed by the reduction in the drag of the side frames.

Front vehicle body structure

The present invention relates to an isoquinoline compound represented by the following formula (I), an optically active form thereof, a pharmaceutically acceptable salt thereof, a water adduct thereof, a hydrate thereof and a solvate thereof, as well as an agent for the prophylaxis and/or treatment of a disease caused by hyperreactivity of poly(ADP-ribose)polymerase, containing the compound, and a poly(ADP-ribose)polymerase inhibitor containing the compound. In addition, this compound is useful as an agent for the prophylaxis and/or treatment of cerebral infarction, particularly as an agent for the prophylaxis and/or treatment of acute cerebral infarction. Furthermore, this compound is useful as a prophylactic and/or therapeutic agent that improves neurological symptoms associated with cerebral infarction, particularly acute cerebral infarction. wherein the symbols are the same as defined in the description.

Isoquinoline compound and pharmaceutical use thereof

The present invention relates to an isoquinoline compound represented by the following formula (I) or (II), an optically active form thereof, a pharmaceutically acceptable salt thereof, a water adduct thereof, a hydrate thereof and a solvate thereof, as well as an agent for the prophylaxis and/or treatment of a disease caused by hyperreactivity of poly(ADP-ribose)polymerase, containing the compound, and a poly(ADP-ribose)polymerase inhibitor containing the compound. In addition, this compound is useful as an agent for the prophylaxis and/or treatment of cerebral infarction, particularly as an agent for the prophylaxis and/or treatment of acute cerebral infarction. 

Isoquinoline compounds and medicinal use thereof

Carboxamide derivatives of the following general formula (I): ##STR1## (wherein R.sup.1 and R.sup.2 are C.sub.1 -C.sub.3 alkyl group or both taken together C.sub.1 -C.sub.3 alkylene group,

Carboxamide derivatives

A novel 1-phenylalkyl-3-phenylurea derivative represented by the following formula (I): ##STR1## wherein R.sup.1 and R.sup.5 represent independently hydrogen, C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.5 alkoxyl or halo; R.sup.2 represents hydrogen or C.sub.1 -C.sub.15 alkyl; R.sup.3 represents C.sub.1 -C.sub.15 alkyl or R.sup.3 represents together with R.sup.2 C.sub.2 -C.sub.9 alkylene; R.sup.4 and R.sup.5 represent independently C.sub.1 -C.sub.5 alkyl, C.sub.1 -C.sub.5 alkoxyl or halo; X represents oxygen or sulfur; Y represents --O--(CH.sub.2).sub.l --O-- wherein l is an integer of 1 to 3 or --(CH.sub.2).sub.p -- wherein p is an integer of 3 to 5; m is 0 or an integer of 1 to 5; and n is 0 or an integer of 1 to 3, is provided. The 1-phenylalkyl-3-phenylurea derivative (I) have the action of reducing cholesterol in blood by ACAT inhibition, and therefore, useful for treating hyperlipemia and atherosclerosis.

1-phenylalkyl-3-phenylurea derivative

Novel 1-phenylakyl-3-phenylurea derivatives represented by the following formula (I): ##STR1## wherein R.sup.1 is an alkyl group of 1 to 8 carbon atoms, an alkoxy group of 1 to 5 carbon atoms or a halogen atom, R.sup.2 is an alkyl group of 1 to 15 carbon atoms, each of R.sup.3 and R.sup.4 is independently an alkyl group of 1 to 5 carbon atoms, m is an integer of 1 to 3, and n is 0 or 1, are provided. The compounds are potent in reducing the cholesterol level in serum, and useful for treating hyperlipemia and atherosclerosis.

1-phenylalkyl-3-phenylurea derivatives

Novel pyrrolecarboxylic acid derivatives represented by the following formula: ##STR1## where R.sup.1 is a hydrogen atom, an alkyl group of 5 to 25 carbon atoms or an alkenyl group of 5 to 25 carbon atoms, R.sup.2 is a hydrogen atom, a phenyl group or an optionally substituted alkyl group of 1 to 10 carbon atoms, and R.sup.3 is a hydrogen atom, an alkyl group of 5 to 25 carbon atoms or an alkenyl group of 5 to 25 carbon atoms, or pharmaceutically acceptable salts thereof are provided. The compounds are highly effective in reducing the level of triglyceride or cholesterol in serum, and useful as an active ingredient of a pharmaceutical composition for treating hyperlipemia and arteriosclerosis.

Pyrrolecarboxylic acid derivatives

Novel diphenylurea derivatives represented by the following formula (I): ##STR1## wherein R.sub.1 is an alkyl group of 5 to 18 carbon atoms, each of R.sub.2 and R.sub.3 is independently an alkyl group of 1 to 5 carbon atoms, an alkoxy group of 1 to 5 carbon atoms or a halogen atom, R.sub.4 is hydrogen atom, an alkyl group of 1 to 5 carbon atoms, an alkoxy group of 1 to 5 carbon atoms or a halogen atom, and X is oxygen atom or sulfur atom, are provided. The compounds are potent in reducing the cholesterol level in serum, and useful for treating hyperlipemia and atherosclerosis.

Growing community of inventors

Tokyo, Japan

Shinya Inoue